Physiol Rev AJP: Heart and Circulatory Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Physiol. Rev. 79: 99-141, 1999;
0031-9333/99 $15.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ROSSINI, A. A.
Right arrow Articles by MORDES, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ROSSINI, A. A.
Right arrow Articles by MORDES, J. P.

PHYSIOLOGICAL REVIEWS   Vol. 79 No. 1 January 1999, pp. 99-141
Copyright ©1999 The American Physiological Society

Induction of Immunologic Tolerance for Transplantation

ALDO A. ROSSINI, DALE L. GREINER, AND JOHN P. MORDES

Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts

Rossini, Aldo A., Dale L. Greiner, and John P. Mordes. Induction of Immunologic Tolerance for Transplantation. Physiol. Rev. 79: 99-141, 1999. --- In the second half of the 20th century, the transplantation of replacement organs and tissues to cure disease has become a clinical reality. Success has been achieved as a direct result of progress in understanding the cellular and molecular biology of the immune system. This understanding has led to the development of immunosuppressive pharmaceuticals that are part of nearly every transplantation procedure. All such drugs are toxic to some degree, however, and their chronic use, mandatory in transplantation, predisposes the patient to the development of infection and cancer. In addition, many of them may have deleterious long-term effects on the function of grafts. New immunosuppressive agents are constantly under development, but organ transplantation remains a therapy that requires patients to choose between the risks of their primary illness and its treatment on the one hand, and the risks of life-long systemic immunosuppression on the other. Alternatives to immunosuppression include modulation of donor grafts to reduce immunogenicity, removal of passenger leukocytes, transplantation into immunologically privileged sites like the testis or thymus, encapsulation of tissue, and the induction of a state of immunologic tolerance. It is the last of these alternatives that has, perhaps, the most promise and most generic applicability as a future therapy. Recent reports documenting long-term graft survival in the absence of immunosuppression suggest that tolerance-based therapies may soon become a clinical reality. Of particular interest to our laboratory are transplantation strategies that focus on the induction of donor-specific T-cell unresponsiveness. The basic biology, protocols, experimental outcomes, and clinical implications of tolerance-based transplantation are the focus of this review.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
T. B. Thornley, N. E. Phillips, B. C. Beaudette-Zlatanova, T. G. Markees, K. Bahl, M. A. Brehm, L. D. Shultz, E. A. Kurt-Jones, J. P. Mordes, R. M. Welsh, et al.
Type 1 IFN Mediates Cross-Talk between Innate and Adaptive Immunity That Abrogates Transplantation Tolerance
J. Immunol., November 15, 2007; 179(10): 6620 - 6629.
[Abstract] [Full Text] [PDF]

Home page
 J Hand Surg Eur VolHome page
F. SCHUIND, D. ABRAMOWICZ, and S. SCHNEEBERGER
Hand Transplantation: The State-of-the-Art
J Hand Surg Eur Vol., February 1, 2007; 32(1): 2 - 17.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Brehm, J. Mangada, T. G. Markees, T. Pearson, K. A. Daniels, T. B. Thornley, R. M. Welsh, A. A. Rossini, and D. L. Greiner
Rapid quantification of naive alloreactive T cells by TNF-{alpha} production and correlation with allograft rejection in mice
Blood, January 15, 2007; 109(2): 819 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. S. Narang and R. I. Mahato
Biological and biomaterial approaches for improved islet transplantation.
Pharmacol. Rev., June 1, 2006; 58(2): 194 - 243.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Pearson, P. Weiser, T. G. Markees, D. V. Serreze, L. S. Wicker, L. B. Peterson, A.-M. Cumisky, L. D. Shultz, J. P. Mordes, A. A. Rossini, et al.
Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice Is Controlled by Allelic Variants of Idd3
Diabetes, August 1, 2004; 53(8): 1972 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. A. Rossini
Autoimmune Diabetes and the Circle of Tolerance
Diabetes, February 1, 2004; 53(2): 267 - 275.
[Abstract] [Full Text]

Home page
 Ann. N. Y. Acad. Sci.Home page
T. PEARSON, T. G. MARKEES, D. V. SERREZE, M. A. PIERCE, L. S. WICKER, L. B. PETERSON, L. D. SHULTZ, J. P. MORDES, A. A. ROSSINI, and D. L. GREINER
Islet Cell Autoimmunity and Transplantation Tolerance: Two Distinct Mechanisms?
Ann. N.Y. Acad. Sci., November 1, 2003; 1005(1): 148 - 156.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
N. A. Turgeon, S. J. Banuelos, L. D. Shultz, B. L. Lyons, N. Iwakoshi, D. L. Greiner, J. P. Mordes, A. A. Rossini, and M. C. Appel
Alloimmune Injury and Rejection of Human Skin Grafts on Human Peripheral Blood Lymphocyte-Reconstituted Non-Obese Diabetic Severe Combined Immunodeficient {beta}2-Microglobulin-Null Mice
Experimental Biology and Medicine, October 1, 2003; 228(9): 1096 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. W. Soper, M. D. Lessard, C. D. Jude, A. J. T. Schuldt, R. M. Bunte, and J. E. Barker
Successful Allogeneic Neonatal Bone Marrow Transplantation Devoid of Myeloablation Requires Costimulatory Blockade
J. Immunol., September 15, 2003; 171(6): 3270 - 3277.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Xu, R. Lucas, M. Schuchmann, S. Kuhnle, T. Meergans, A. P. Barreiros, A. W. Lohse, G. Otto, and A. Wendel
GM-CSF Restores Innate, But Not Adaptive, Immune Responses in Glucocorticoid-Immunosuppressed Human Blood In Vitro
J. Immunol., July 15, 2003; 171(2): 938 - 947.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Pearson, T. G. Markees, D. V. Serreze, M. A. Pierce, M. P. Marron, L. S. Wicker, L. B. Peterson, L. D. Shultz, J. P. Mordes, A. A. Rossini, et al.
Genetic Disassociation of Autoimmunity and Resistance to Costimulation Blockade-Induced Transplantation Tolerance in Nonobese Diabetic Mice
J. Immunol., July 1, 2003; 171(1): 185 - 195.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
D. O. Taylor
Cardiac transplantation: drug regimens for the 21st century
Ann. Thorac. Surg., June 1, 2003; 75(90060): S72 - 78.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. E. Phillips, T. G. Markees, J. P. Mordes, D. L. Greiner, and A. A. Rossini
Blockade of CD40-Mediated Signaling Is Sufficient for Inducing Islet But Not Skin Transplantation Tolerance
J. Immunol., March 15, 2003; 170(6): 3015 - 3023.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Pearson, T. G. Markees, L. S. Wicker, D. V. Serreze, L. B. Peterson, J. P. Mordes, A. A. Rossini, and D. L. Greiner
NOD Congenic Mice Genetically Protected From Autoimmune Diabetes Remain Resistant to Transplantation Tolerance Induction
Diabetes, February 1, 2003; 52(2): 321 - 326.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Forman, R. M. Welsh, T. G. Markees, B. A. Woda, J. P. Mordes, A. A. Rossini, and D. L. Greiner
Viral Abrogation of Stem Cell Transplantation Tolerance Causes Graft Rejection and Host Death by Different Mechanisms
J. Immunol., June 15, 2002; 168(12): 6047 - 6056.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
D. PIPELEERS, B. KEYMEULEN, L. CHATENOUD, C. HENDRIECKX, Z. LING, C. MATHIEU, B. ROEP, and D. YSEBAERT
A View on Beta Cell Transplantation in Diabetes
Ann. N.Y. Acad. Sci., April 1, 2002; 958(1): 69 - 76.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. N. Iwakoshi, T. G. Markees, N. Turgeon, T. Thornley, A. Cuthbert, J. Leif, N. E. Phillips, J. P. Mordes, D. L. Greiner, and A. A. Rossini4
Skin Allograft Maintenance in a New Synchimeric Model System of Tolerance
J. Immunol., December 1, 2001; 167(11): 6623 - 6630.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. Bosi, S. Braghi, P. Maffi, M. Scirpoli, F. Bertuzzi, G. Pozza, A. Secchi, and E. Bonifacio
Autoantibody Response to Islet Transplantation in Type 1 Diabetes
Diabetes, November 1, 2001; 50(11): 2464 - 2471.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Seung, N. Iwakoshi, B. A. Woda, T. G. Markees, J. P. Mordes, A. A. Rossini, and D. L. Greiner
Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice
Blood, March 15, 2000; 95(6): 2175 - 2182.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. M. Welsh, T. G. Markees, B. A. Woda, K. A. Daniels, M. A. Brehm, J. P. Mordes, D. L. Greiner, and A. A. Rossini
Virus-Induced Abrogation of Transplantation Tolerance Induced by Donor-Specific Transfusion and Anti-CD154 Antibody
J. Virol., March 1, 2000; 74(5): 2210 - 2218.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
N. N. Iwakoshi, J. P. Mordes, T. G. Markees, N. E. Phillips, A. A. Rossini, and D. L. Greiner
Treatment of Allograft Recipients with Donor-Specific Transfusion and Anti-CD154 Antibody Leads to Deletion of Alloreactive CD8+ T Cells and Prolonged Graft Survival in a CTLA4-Dependent Manner
J. Immunol., January 1, 2000; 164(1): 512 - 521.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online